Private company
Nippon Shinyaku
Logo: nippon-shinyaku.co.jp4
Japanese pharmaceutical company
Nippon Shinyaku Co., Ltd. is a Japanese pharmaceutical company headquartered in Kyoto that markets prescription drugs and functional foods.3 Wikipedia text CC BY-SA 4.0
Last updated Oct 21, 2026.
Overview
- Industrypharmaceutical industry1
- HeadquartersKyoto Prefecture1
- Websitewww.nippon-shinyaku.co.jp
See how the biggest companies compare on our leaderboards

Nippon Shinyaku Co., Ltd. is a Japanese pharmaceutical company headquartered in Kyoto that markets prescription drugs and functional foods.3
Corporate structure
Nippon Shinyaku sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
- Nippon Shinyaku Kyoto Prefecture
- CAPRICOR THERAPEUTICS, INC. Stake · Beverly Hills, California, United States
Built from major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.
Timeline
- Sep 29, 1919Founded Founded1
Calendar
Drug trials and FDA: coming up
- Dec 2026Phase 2 trial readout expected Phase 2 trial of NS-229 in Eosinophilic Granulomatosis With Polyangiitis, run by NS Pharma, Inc.: primary completion expected Dec 2026 (ClinicalTrials.gov NCT06046222).6
- Feb 26, 2027Phase 2 trial readout expected Phase 2 trial of NS-089/NCNP-02 in Duchenne Muscular Dystrophy, run by NS Pharma, Inc.: primary completion expected Feb 26, 2027 (ClinicalTrials.gov NCT05996003).7
- Apr 30, 2027Phase 2 trial readout expected Phase 2 trial of NS-089/NCNP-02 in Duchenne Muscular Dystrophy (DMD): primary completion expected Apr 30, 2027 (ClinicalTrials.gov NCT05135663).8
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
Stakes it holds
Nippon Shinyaku has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).
- CAPRICOR THERAPEUTICS, INC.SC 13G/A Oct 17, 2023 to Sep 24, 20249
SEC filer profile
How Nippon Shinyaku is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
Links
- Websitewww.nippon-shinyaku.co.jp1
- WikipediaNippon Shinyaku
- More imagesWikimedia Commons
- WikidataQ11508222
- SEC EDGARCIK 1361865
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataNippon Shinyaku on Wikidata
- 2SEC EDGARNippon Shinyaku filings on SEC EDGAR
- 3WikipediaNippon Shinyaku on Wikipedia
- 4Company websiteNippon Shinyaku logo
- 5Wikimedia CommonsNippon Shinyaku photo by Shinyakunippon, CC BY-SA 4.0
- 6
- 7
- 8ClinicalTrials.govClinicalTrials.gov NCT05135663: Extension Study of NS-089/NCNP-02 in DMD
- 9